Abstract
Purpose:To compare the outcomes of treatment with intravitreal bevacizumab (IVB) versus observation in central serous chorioretinopathy (CSCR).Methods:In a retrospective comparative study, records of 45 patients with CSCR were reviewed. Twenty-two patients received IVB (1.25 mg/0.05 ml) while 23 subjects were observed. All subjects underwent measurement of best corrected visual acuity (BCVA) and intraocular pressure (IOP), dilated fundus examination and optical coherence tomography (OCT) imaging at baseline and follow up visits. Outcome measures included central macular thickness (CMT) and BCVA in logarithm of minimum angle of resolution (logMAR) notations.Results:Mean age was 44.1 ± 9.3 (range: 24 to 64) years and mean follow-up period was 10.4 ± 11.2 (range: 3 to 43; median: 6) months. All patients demonstrated resolution of neurosensory detachment and improvement in visual acuity. At final visit, there was no significant difference in mean CMT between the IVB and observation groups (275 vs 284 μm, P> 0.05). Mean baseline logMAR visual acuity was 0.38 ± 0.24 in the IVB group which improved to 0.24 ± 0.31 at final follow-up (P = 0.011); mean baseline logMAR visual acuity was 0.42 ± 0.28 in the observation group and improved to 0.12 ± 0.18 (P = 0.001). Visual improvement was more marked in the observation group (0.30 vs 0.14 logMAR, P< 0.05) and mean final visual acuity was also significantly better (P = 0.05).Conclusion:There was no significant difference between IVB injection and observation in terms of anatomical outcomes of treatment for CSCR. In terms of visual outcomes, observation was superior to IVB injection.
Highlights
Central serous chorioretinopathy (CSCR) is an idiopathic condition characterized by serous neurosensory retinalReceived: 23-03-2015Accepted: 18-06-2015Access this article onlineQuick Response Code: Website: www.jovr.org detachment at the posterior pole, often in association with serous retinal pigment epithelial (RPE) detachment.[1]
Patients who were treated with an intravitreal injection of 0.05 ml (1.25 mg) bevacizumab (Avastin, Roche, Basel, Switzerland) were considered as the intravitreal bevacizumab (IVB) injection group and subjects who were only observed without any medication or intervention served as the control group
Baseline logarithm of minimum angle of resolution (logMAR) visual acuity and central macular thickness (CMT) were comparable between the two groups (P = 0.151)
Summary
Quick Response Code: Website: www.jovr.org detachment at the posterior pole, often in association with serous retinal pigment epithelial (RPE) detachment.[1] CSCR patients usually have good visual prognosis. A number of patients may develop visual impairment due to persistent RPE and photoreceptor damage.[2,3].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
